CA3060518A1 - Methods for inducing chondrogenesis - Google Patents

Methods for inducing chondrogenesis Download PDF

Info

Publication number
CA3060518A1
CA3060518A1 CA3060518A CA3060518A CA3060518A1 CA 3060518 A1 CA3060518 A1 CA 3060518A1 CA 3060518 A CA3060518 A CA 3060518A CA 3060518 A CA3060518 A CA 3060518A CA 3060518 A1 CA3060518 A1 CA 3060518A1
Authority
CA
Canada
Prior art keywords
lag
compound
pharmaceutically acceptable
solvate
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3060518A
Other languages
English (en)
French (fr)
Inventor
Peter G. Schultz
Arnab K. Chatterjee
Timothy M. Wright
John Wisler
Vadim KLYUSHNICHENKO
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CA3060518A1 publication Critical patent/CA3060518A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/452—Lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/24—Materials or treatment for tissue regeneration for joint reconstruction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3060518A 2017-04-24 2018-04-23 Methods for inducing chondrogenesis Pending CA3060518A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762489397P 2017-04-24 2017-04-24
US62/489,397 2017-04-24
PCT/US2018/028939 WO2018200411A1 (en) 2017-04-24 2018-04-23 Methods for inducing chondrogenesis

Publications (1)

Publication Number Publication Date
CA3060518A1 true CA3060518A1 (en) 2018-11-01

Family

ID=63919101

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3060518A Pending CA3060518A1 (en) 2017-04-24 2018-04-23 Methods for inducing chondrogenesis

Country Status (10)

Country Link
US (1) US20210361600A1 (https=)
EP (1) EP3615021A4 (https=)
JP (2) JP2020517597A (https=)
KR (1) KR20190137904A (https=)
CN (1) CN110809468A (https=)
AU (1) AU2018257769A1 (https=)
CA (1) CA3060518A1 (https=)
MA (1) MA48479A (https=)
RU (1) RU2019136884A (https=)
WO (1) WO2018200411A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186307B2 (en) 2019-02-13 2025-01-07 Yale University Methods of treating epilepsy
FI129515B (en) 2020-11-06 2022-03-31 Salarusta Oy FOR USE IN THE PREVENTION AND / OR TREATMENT OF A DISEASE OR CONDITION RELATED TO THE DEGRADATION AND / OR DISTURBANCE OF THE DEGREE OF MONTOOSASE AND / OR INTEGRITY

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464065B2 (en) * 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
HK1224172A1 (zh) * 2013-03-15 2017-08-18 加州生物医学研究所 用於诱导软骨形成的化合物和方法
DK3143026T3 (da) * 2014-05-13 2024-09-30 Novartis Ag Forbindelser og sammensætninger til induktion af chondrogenese

Also Published As

Publication number Publication date
AU2018257769A1 (en) 2019-11-07
RU2019136884A (ru) 2021-05-25
US20210361600A1 (en) 2021-11-25
JP2023071181A (ja) 2023-05-22
RU2019136884A3 (https=) 2021-08-03
EP3615021A1 (en) 2020-03-04
WO2018200411A1 (en) 2018-11-01
EP3615021A4 (en) 2020-12-30
JP2020517597A (ja) 2020-06-18
MA48479A (fr) 2020-03-04
CN110809468A (zh) 2020-02-18
KR20190137904A (ko) 2019-12-11

Similar Documents

Publication Publication Date Title
US11560378B2 (en) Treatment of osteoarthritis
US20210030752A1 (en) Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissue
Hurtig et al. Two compartment pharmacokinetic model describes the intra‐articular delivery and retention of rhprg4 following ACL transection in the Yucatan mini pig
Rudnik‐Jansen et al. Local controlled release of corticosteroids extends surgically induced joint instability by inhibiting tissue healing
JP2023071181A (ja) 軟骨形成を誘導するための方法
Wegner et al. The effect of losartan on the development of post-traumatic joint stiffness in a rat model
JP7353663B2 (ja) Ｇａｂａａ受容体リガンド
Allen et al. Gait and behavior in an IL1β‐mediated model of rat knee arthritis and effects of an IL1 antagonist
Costa et al. Analgesic efficacy of tapentadol in chronic joint disorders in horses: plasma serotonin concentration and adrenocortical response as biomarkers of pain-induced stress
CN105491998B (zh) 预防骨关节炎的方法和化合物
CA3004506C (en) Use of n-(5-(3-(7-(3- fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide in the treatment of osteoarthritis
US20230414508A1 (en) Liposomes encapsulating adenosine
Jin et al. Effects of Low-Dose Dexamethasone Regimens on Early Clinical Outcomes After Unicompartmental Knee Arthroplasty: A Retrospective Cohort Study
Sassaroli et al. Clinical effects of intra-articular injections of stanozolol in canine patients affected by spontaneous osteoarthritis
WO2024088712A1 (en) Mglur5 receptor antagonists for use in prevention and/or treatment of bone marrow lesions (bml) and/or osteoporosis, cartilage loss, osteosclerosis, osteitis in a mammal
WO2025171165A1 (en) Therapeutics and methods for treating osteoarthritis
Hurtig et al. A Two Compartment Pharmacokinetic Model Describes the Intra-articular Delivery and Retention of rhPRG4 Following ACL Intra articular Delivery and Retention of rhPRG4 Following ACL Transection in the Yucatan Mini Pig
HK40045419A (en) Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
Gonçalves et al. 546 Dual inhibition ofii-1-induced nf-κb activation and inos enzyme activity in human chondrocytes by natural and commercial α-pinene
Möller et al. 548 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL ON THE EFFECTS OF CHONDROITIN SULPHATE IN PATIENTS WITH KNEE OSTEOARTHRITIS AND PSORIASIS
Santos et al. 547 HYLAN GF 20 FORMULATIONS TO EXTEND INTRAARTICULAR DELIVERY OF NSAIDS COX-2 INHIBITORS AND MMP INHIBITORS
HK1231392B (zh) 用於杀死衰老细胞和用於治疗衰老相关疾病和病症的方法和组合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220916